These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 18483151)

  • 1. Expression and functional analysis of dopamine receptor subtype 2 and somatostatin receptor subtypes in canine cushing's disease.
    de Bruin C; Hanson JM; Meij BP; Kooistra HS; Waaijers AM; Uitterlinden P; Lamberts SW; Hofland LJ
    Endocrinology; 2008 Sep; 149(9):4357-66. PubMed ID: 18483151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
    van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.
    Tateno T; Kato M; Tani Y; Oyama K; Yamada S; Hirata Y
    Endocr J; 2009; 56(4):579-84. PubMed ID: 19318729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein expression of somatostatin receptor 2, somatostatin receptor 5 and dopamine D2 receptor in normal pituitary gland and ACTH-secreting pituitary adenoma in dogs.
    Sato A; Hara Y
    Res Vet Sci; 2018 Aug; 119():61-66. PubMed ID: 29864631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-arrestin expression in corticotroph tumor cells is modulated by glucocorticoids.
    Gatto F; Feelders RA; van der Pas R; van Koetsveld P; Bruzzone E; Arvigo M; Dogan F; Lamberts S; Ferone D; Hofland L
    J Endocrinol; 2020 Apr; 245(1):101-113. PubMed ID: 32027601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas.
    de Bruin C; Pereira AM; Feelders RA; Romijn JA; Roelfsema F; Sprij-Mooij DM; van Aken MO; van der Lelij AJ; de Herder WW; Lamberts SW; Hofland LJ
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1118-24. PubMed ID: 19141584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of genes related to corticotropin production and glucocorticoid feedback in corticotroph adenomas of dogs with Cushing's disease.
    Teshima T; Hara Y; Takekoshi S; Teramoto A; Osamura RY; Tagawa M
    Domest Anim Endocrinol; 2009 Jan; 36(1):3-12. PubMed ID: 18818046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of somatostatin analogs in Cushing's disease.
    van der Hoek J; Lamberts SW; Hofland LJ
    Pituitary; 2004; 7(4):257-64. PubMed ID: 16132202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cushing's disease in dogs and humans.
    de Bruin C; Meij BP; Kooistra HS; Hanson JM; Lamberts SW; Hofland LJ
    Horm Res; 2009 Jan; 71 Suppl 1():140-3. PubMed ID: 19153526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
    J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.
    Hofland LJ; van der Hoek J; Feelders R; van Aken MO; van Koetsveld PM; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; de Herder WW; Beckers A; Lamberts SW
    Eur J Endocrinol; 2005 Apr; 152(4):645-54. PubMed ID: 15817922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin and somatostatin receptors in Cushing's disease.
    Hofland LJ
    Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
    Zatelli MC; Piccin D; Tagliati F; Bottoni A; Ambrosio MR; Margutti A; Scanarini M; Bondanelli M; Culler MD; degli Uberti EC
    J Mol Endocrinol; 2005 Oct; 35(2):333-41. PubMed ID: 16216913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
    Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
    Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease.
    Hayashi K; Inoshita N; Kawaguchi K; Ibrahim Ardisasmita A; Suzuki H; Fukuhara N; Okada M; Nishioka H; Takeuchi Y; Komada M; Takeshita A; Yamada S
    Eur J Endocrinol; 2016 Feb; 174(2):213-26. PubMed ID: 26578638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The genomic profiling and MAMLD1 expression in human and canines with Cushing's disease.
    Wang A; Neill SG; Newman S; Tryfonidou MA; Ioachimescu A; Rossi MR; Meij BP; Oyesiku NM
    BMC Endocr Disord; 2021 Sep; 21(1):185. PubMed ID: 34517852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin Receptor as a Molecular Imaging Target in Human and Canine Cushing Disease.
    De Ravin E; Phan HAT; Harmsen S; Cho SS; Teng CW; Petersson EJ; White C; Galban EM; Hess R; Lee JYK
    World Neurosurg; 2021 May; 149():94-102. PubMed ID: 33601082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro.
    de Bruin C; Feelders RA; Waaijers AM; van Koetsveld PM; Sprij-Mooij DM; Lamberts SW; Hofland LJ
    J Mol Endocrinol; 2009 Jan; 42(1):47-56. PubMed ID: 18852217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
    Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
    Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.
    Neto LV; Machado Ede O; Luque RM; Taboada GF; Marcondes JB; Chimelli LM; Quintella LP; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
    J Clin Endocrinol Metab; 2009 Jun; 94(6):1931-7. PubMed ID: 19293270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.